4.6 Article

Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array

Journal

MICROMACHINES
Volume 13, Issue 3, Pages -

Publisher

MDPI
DOI: 10.3390/mi13030478

Keywords

biosensor; blood glucose; tissue interstitial fluid; continuous glucose sensing; microneedle; micro transfer

Ask authors/readers for more resources

In this research, a continuous blood glucose monitoring system (CGMS) is developed, which includes a microneedle-array blood glucose sensor, a circuit module, and a transmission module placed in a wearable device. The system enables continuous blood glucose sensing and wireless data transmission. Through various experiments and analyses, the feasibility and effectiveness of the system are demonstrated.
A continuous blood glucose monitoring system (CGMS) which include a microneedle-array blood glucose sensor, a circuit module, and a transmission module placed in a wearable device is developed in this research. When in use, the wearable device is attached to the human body with the microneedle array inserted under the skin for continuous blood glucose sensing, and the measured signals are transmitted wirelessly to a mobile phone or computer for analysis. The purpose of this study is to replace the conventionally used method of puncture for blood collection and test strips are used to measure the blood glucose signals. The microneedle sensor of this CGMS uses a 1 mm length needle in a 3 mm x 3 mm microneedle array for percutaneous minimally invasive blood glucose measurement. This size of microneedle does not cause bleeding damage to the body when used. The microneedle sensor is placed under the skin and their solutions are discussed. The blood glucose sensor measured the in vitro simulant fluid with a glucose concentration range of 50 similar to 400 mg/dL. In addition, a micro-transfer method is developed to accurately deposit the enzyme onto the tip of the microneedle, after which cyclic voltammetry (CV) is used to measure the glucose simulation solution to verify whether the difference in the amount of enzyme on each microneedle is less than 10%. Finally, various experiments and analyses are carried out to reduce the size of the device, test effective durability (approximately 7 days), and the feasibility of minimally invasive CGMS is evaluated by tests on two persons.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available